OP Div, CFO Change: Olema Oncology Reports Q3 Results
Olema Oncology reported robust cash and enrollment for palazestrant trials while appointing a new CFO. The company remains on track to announce pivotal Phase 3 data in 2027, deeming it a key catalyst.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed